Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Lucid Diagnostics (LUCD) over the last 4 years, with Q3 2025 value amounting to $27.1 million.

  • Lucid Diagnostics' Cash from Financing Activities rose 2876170.21% to $27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.0 million, marking a year-over-year increase of 11851.97%. This contributed to the annual value of $48.2 million for FY2024, which is 6377.46% up from last year.
  • Latest data reveals that Lucid Diagnostics reported Cash from Financing Activities of $27.1 million as of Q3 2025, which was up 2876170.21% from $16.5 million recorded in Q2 2025.
  • In the past 5 years, Lucid Diagnostics' Cash from Financing Activities registered a high of $27.1 million during Q3 2025, and its lowest value of $1000.0 during Q4 2022.
  • Over the past 4 years, Lucid Diagnostics' median Cash from Financing Activities value was $8.3 million (recorded in 2023), while the average stood at $10.0 million.
  • Over the last 5 years, Lucid Diagnostics' Cash from Financing Activities had its largest YoY gain of 49990000.0% in 2023, and its largest YoY loss of 8569.2% in 2023.
  • Lucid Diagnostics' Cash from Financing Activities (Quarter) stood at $1000.0 in 2022, then soared by 499900.0% to $5.0 million in 2023, then skyrocketed by 259.98% to $18.0 million in 2024, then surged by 50.73% to $27.1 million in 2025.
  • Its Cash from Financing Activities was $27.1 million in Q3 2025, compared to $16.5 million in Q2 2025 and $15.4 million in Q1 2025.